1. Home
  2. KXIN vs ACXP Comparison

KXIN vs ACXP Comparison

Compare KXIN & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$5.30

Market Cap

7.0M

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.38

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
ACXP
Founded
2015
2017
Country
China
United States
Employees
13
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0M
6.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KXIN
ACXP
Price
$5.30
$1.38
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
60.1K
89.7K
Earning Date
11-26-2019
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.29
52 Week High
$22.00
$8.34

Technical Indicators

Market Signals
Indicator
KXIN
ACXP
Relative Strength Index (RSI) 54.77 39.45
Support Level $5.30 $1.36
Resistance Level $6.09 $1.75
Average True Range (ATR) 0.60 0.13
MACD 0.09 -0.00
Stochastic Oscillator 64.21 11.11

Price Performance

Historical Comparison
KXIN
ACXP

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: